Unique Quantitative Trait Loci in Synergy Permanently Improve Diastolic Dysfunction

Canadian Journal of Cardiology

Volumn 29, Issue 10, 2013, Pages 1302-1309

  Chauvet, Cristina ^a   Crespo, Kimberley ^a   Shi, Yanfen ^b   Gelinas, Danielle ^b   Duval, Francine ^b   L'Heureux, Nathalie ^b   Nattel, Stanley ^b   Tardif, Jean Claude ^b   Deng, Alan Y ^a  

^a CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

^b MONTREAL HEART INSTITUTE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CHROMOSOME; CONGENIC STRAIN; CONTROLLED STUDY; DAHL SALT SENSITIVE RAT; DIASTOLIC DYSFUNCTION; ECHOCARDIOGRAPHY; HEART LEFT VENTRICLE HYPERTROPHY; LEWIS RAT; LONGITUDINAL STUDY; MALE; NONHUMAN; PHENOTYPE; QUANTITATIVE TRAIT LOCUS; RAT;

ANIMALS; ANIMALS, CONGENIC; BLOOD PRESSURE; CHROMOSOME MAPPING; DIASTOLE; DISEASE MODELS, ANIMAL; ECHOCARDIOGRAPHY; GENETIC THERAPY; HYPERTROPHY, LEFT VENTRICULAR; MALE; PHENOTYPE; QUANTITATIVE TRAIT LOCI; RATS; RATS, INBRED DAHL; VENTRICULAR DYSFUNCTION, LEFT; VENTRICULAR FUNCTION, LEFT;

EID: 84884592927     PISSN: 0828282X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cjca.2013.03.012     Document Type: Article

References (28)

1. Neubauer S. The failing heart-an engine out of fuel. NEngl J Med 2007, 356:1140-1151.
2. Bhatia R.S., Tu J.V., Lee D.S., et al. Outcome of heart failure with preserved ejection fraction in a population-based study. NEngl J Med 2006, 355:260-269.
3. Brutsaert D.L., De Keulenaer G.W. Diastolic heart failure: a myth. Curr Opin Cardiol 2006, 21:240-248.
4. Owan T.E., Hodge D.O., Herges R.M., Jacobsen S.J., Roger V.L., Redfield M.M. Trends in prevalence and outcome of heart failure with preserved ejection fraction. NEngl J Med 2006, 355:251-259.
5. Bombelli M., Facchetti R., Carugo S., et al. Left ventricular hypertrophy increases cardiovascular risk independently of in-office and out-of-office blood pressure values. JHypertens 2009, 27:2458-2464.
6. Lorell B.H., Carabello B.A. Left ventricular hypertrophy. Circulation 2000, 102:470-479.
7. Schocken D.D., Benjamin E.J., Fonarow G.C., et al. Prevention of heart failure. Circulation 2008, 117:2544-2565.
8. Arnett D. Genetic contributions to left ventricular hypertrophy. Curr Hypertens Rep 2000, 2:50-55.
9. Arnett D.K., Devereux R.B., Rao D.C., et al. Novel genetic variants contributing to left ventricular hypertrophy: the HyperGEN study. JHypertens 2009, 27:1585-1593.
10. Llamas B., Jiang Z., Rainville M.L., Picard S., Deschepper C. Distinct QTLs are linked to cardiac left ventricular mass in a sex-specific manner in a normotensive inbred rat intercross. Mammalian Genome 2005, 16:700-711.
11. Chauvet C., Menard A., Tremblay J., et al. Cardiac pathways distinguish two epistatic modules enacting BP quantitative trait loci and candidate gene analysis. Hypertens Res 2009, 32:631-637.
12. Deng A.Y., Nattel S., Shi Y., et al. Distinct genomic replacements from Lewis correct diastolic dysfunction, attenuate hypertension, and reduce left ventricular hypertrophy in Dahl salt-sensitive rats. JHypertens 2008, 26:1935-1943.
13. Doi R., Masuyama T., Yamamoto K., et al. Development of different phenotypes of hypertensive heart failure: systolic versus diastolic failure in Dahl salt-sensitive rats. JHypertens 2000, 18:111-120.
14. Klotz S., Hay I., Zhang G., Maurer M., Wang J., Burkhoff D. Development of heart failure in chronic hypertensive Dahl rats: focus on heart failure with preserved ejection fraction. Hypertension 2006, 47:901-911.
15. Gottdiener J.S., McClelland R.L., Marshall R., et al. Outcome of congestive heart failure in elderly persons: influence of left ventricular systolic function: the Cardiovascular Health Study. Ann Intern Med 2002, 137:631-639.
16. Charron S., Duong C., Menard A., et al. Epistasis, not numbers, regulates functions of clustered Dahl rat quantitative trait loci applicable to human hypertension. Hypertension 2005, 46:1300-1308.
17. Chauvet C., Charron S., Menard A., Xiao C., Roy J., Deng A.Y. Submegabase resolution of epistatically interacting quantitative trait loci for blood pressure applicable for essential hypertension. JHypertens 2008, 26:893-901.
18. Chauvet C., Crespo K., Menard A., et al. alpha-Kinase 2 is a novel candidate gene for inherited hypertension in Dahl rats. JHypertens 2011, 29:1320-1326.
19. Charo I.F., Taubman M.B. Chemokines in the pathogenesis of vascular disease. Circ Res 2004, 95:858-866.
20. Chauvet C., Menard A., Xiao C., et al. Novel genes as primary triggers for polygenic hypertension. JHypertens 2012, 30:81-86.
21. Fernandez E.J., Lolis E. Structure, function, and inhibition of chemokines. Annu Rev Pharmacol Toxicol 2012, 42:469-499.
22. Frangogiannis N.G., Entman M.L. Chemokines in myocardial ischemia. Trends Cardiovasc Med 2005, 15:163-169.
23. Peters W., Charo I.F. Involvement of chemokine receptor 2 and its ligand, monocyte chemoattractant protein-1, in the development of atherosclerosis: lessons from knockout mice. Curr Opin Lipidol 2001, 12:175-180.
24. Franke A., McGovern D.P.B., Barrett J.C., et al. Genome-wide meta-analysis increases to 71 the number of confirmed Crohn's disease susceptibility loci. Nat Genet 2010, 42:1118-1125.
25. Szalai C., Duba J., Prohászka Z., et al. Involvement of polymorphisms in the chemokine system in the susceptibility for coronary artery disease (CAD): coincidence of elevated Lp(a) and MCP-1 -2518 G/G genotype in CAD patients. Atherosclerosis 2001, 158:233-239.
26. Boring L., Gosling J., Cleary M., Charo I.F. Decreased lesion formation in CCR2-/- mice reveals a role for chemokines in the initiation of atherosclerosis. Nature 1998, 394:894-897.
27. Blencke S., Ullrich A., Daub H. Mutation of threonine 766 in the epidermal growth factor receptor reveals a hotspot for resistance formation against selective tyrosine kinase inhibitors. JBiol Chem 2003, 278:15435-15440.
28. Bustos O., Naik S., Ayers G., et al. Evolution of the Schlafen genes, a gene family associated with embryonic lethality, meiotic drive, immune processes and orthopoxvirus virulence. Gene 2009, 447:1-11.